Cosmos Holdings (COSM) AI Stock Analysis

• Market Cap: $9.82M
• Dividend Yield: N/A
• Average Volume (3M): 181.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.78
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 64
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -1.72
• Shares Outstanding: 27,284,658
• 10 Day Avg. Volume: 283,372
• 30 Day Avg. Volume: 181,663
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.20
• Price to Cash Flow (P/CF): 3.80
• P/FCF Ratio: 2.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Cosmos Holdings' stock is under significant pressure due to financial difficulties and lackluster technical indicators. The company's struggle with profitability and high leverage are major concerns, reflected in its low financial performance score. Technical analysis suggests a bearish trend, and with a negative P/E ratio, valuation remains poor. These factors contribute to a low overall stock score.

Cosmos Holdings Business Overview & Revenue Model

Company Description

Cosmos Holdings Inc. is a multinational healthcare group operating primarily in the pharmaceutical sector. The company focuses on the research, development, and distribution of pharmaceutical products, including branded and generic medicines, nutraceuticals, and over-the-counter products. With operations spanning various countries, Cosmos Holdings aims to improve health and wellness outcomes through an integrated approach to healthcare delivery.

How the Company Makes Money

Cosmos Holdings generates revenue primarily through the sale of its pharmaceutical products. The company's revenue model is centered around the distribution of branded and generic medications to pharmacies, hospitals, and clinics. In addition to its core pharmaceutical offerings, Cosmos Holdings also engages in the sale of nutraceuticals and other health-related products. Strategic partnerships with healthcare providers and distribution networks play a crucial role in broadening the company's market reach and enhancing its earnings potential. By leveraging its extensive distribution network and product portfolio, Cosmos Holdings continues to expand its presence in the global healthcare market.

Cosmos Holdings Financial Statement Overview

Summary

Cosmos Holdings exhibits challenging financial performance with negative EBIT and net income, indicating operational inefficiencies. The high debt-to-equity ratio poses financial risk, and persistent negative cash flows reflect liquidity challenges. Minor revenue and equity improvements are overshadowed by significant financial issues.

Income Statement

Cosmos Holdings exhibits a challenging financial performance with consistently negative EBIT and net income, indicating operational inefficiencies. The gross profit margin remains low, and recent revenue growth is moderate, but the company has not been able to translate it to profitability. The negative EBITDA and EBIT margins further highlight the lack of operational profitability.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, reflecting significant leverage, which poses financial risk. The equity ratio indicates moderate reliance on equity financing. Recent improvements in stockholders' equity are positive but overshadowed by substantial liabilities, suggesting potential financial instability.

Cash Flow

Cash flow analysis shows persistent negative operating and free cash flows, indicating liquidity challenges. The negative free cash flow growth rate highlights ongoing cash consumption. The cash flow from operations does not cover net income, reflecting cash management issues.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
56.04M	53.38M	50.35M	56.24M	55.41M	39.68M
	Gross Profit
4.40M	4.35M	5.96M	8.33M	8.06M	3.66M
	EBIT
-20.16M	-21.83M	-7.47M	-4.53M	2.71M	-21.93K
	EBITDA
-18.29M	-17.06M	-8.90M	-3.82M	3.18M	-988.59K
	Net Income Common Stockholders
-20.39M	-18.54M	-13.83M	-7.96M	820.79K	-3.30M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
52.00	3.85M	20.76M	293.18K	851.19K	281.86K
	Total Assets
52.00	66.01M	68.04M	49.43M	43.84M	23.88M
	Total Debt
15.87K	12.42M	12.03M	27.12M	32.04M	19.29M
	Net Debt
15.82K	8.59M	-8.72M	26.84M	31.41M	19.25M
	Total Liabilities
17.03K	29.97M	28.38M	45.05M	48.01M	30.34M
	Stockholders Equity
-16.98K	36.04M	39.66M	4.38M	-4.16M	-6.46M
Cash Flow		Free Cash Flow
-7.55M	-24.80M	-15.25M	-7.99M	-11.62M	-5.46M
	Operating Cash Flow
-3.65M	-15.64M	-14.87M	-7.10M	-11.50M	-4.79M
	Investing Cash Flow
-3.15M	-13.76M	-21.50K	-826.82K	-117.74K	588.93K
	Financing Cash Flow
8.44M	12.69M	35.05M	7.27M	12.46M	3.59M

Cosmos Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COSM, the sentiment is Neutral. The current price of 0.4 is above the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.48, and below the 200-day MA of 0.79, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 48.65 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for COSM.

Cosmos Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
TXMD	47 Neutral	$12.85M	―	-8.16%	―	35.25%	81.05%
BFRI	44 Neutral	$7.69M	―	-384.98%	―	9.54%	74.28%
AYTU	43 Neutral	$6.48M	―	-18.06%	―	-30.19%	75.92%
FLGC	42 Neutral	$10.11M	―	-291.50%	―	-22.58%	82.94%
COSM	38 Underperform	$9.82M	―	-58.30%	―	―	―